Daxotel80 mg/vial

Daxotel is a taxane-class chemotherapy agent used, under the supervision of an oncologist, for the treatment of several solid tumors. It is administered only by intravenous (IV) infusion in a hospital or oncology chemotherapy setting.

FDA-Approved / Established Indications

• Breast cancer: Locally advanced or metastatic breast cancer, as a single agent after failure of prior chemotherapy, or in combination with doxorubicin and cyclophosphamide as adjuvant therapy for operable node-positive breast cancer.
• Non-small cell lung cancer (NSCLC): Locally advanced or metastatic NSCLC, as a single agent after platinum-based chemotherapy failure, or in combination with cisplatin for chemotherapy-naive patients.
• Metastatic castration-resistant prostate cancer: In combination with prednisone.
• Advanced gastric adenocarcinoma: In combination with cisplatin and fluorouracil, in patients who have not received prior chemotherapy for advanced disease.
• Squamous cell carcinoma of the head and neck: In combination with cisplatin and fluorouracil, for induction treatment of locally advanced disease.

Daxotel is always used as part of a physician-directed chemotherapy protocol; it is never self-administered or used outside the combination regimens specified above without medical supervision.

Each vial of Docetaxel Trihydrate concentrate for solution for infusion contains docetaxel (as trihydrate) as the active ingredient, typically supplied in strengths such as 20 mg/1 mL, 20 mg/2 mL, 80 mg/4 mL, or 80 mg/8 mL single-dose vials (concentration approximately 10 mg/mL, formulation dependent on manufacturer). It also contains polysorbate 80 and other excipients used to solubilize the drug; formulations may vary with or without ethanol depending on the manufacturer. Always check the product label of the specific brand dispensed for exact strength and excipients.

Daxotel is a semi-synthetic taxane derived from the needles of the European yew tree (Taxus baccata). It is a cytotoxic antineoplastic (anti-cancer) medicine that works by interfering with the normal function of microtubules, structures essential for cell division. Daxotel is given exclusively as a hospital-administered intravenous infusion by oncology specialists, as part of established chemotherapy protocols for various solid-organ cancers.

Daxotel belongs to the taxane class of antineoplastic agents, classified as an antimicrotubule (mitotic inhibitor) cytotoxic chemotherapy drug.

Docetaxel Trihydrate acts by binding to free tubulin and promoting its assembly into stable microtubules while simultaneously inhibiting their disassembly (depolymerization). This disrupts the dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cell functions, arresting cells in the G2/M phase of the cell cycle and ultimately leading to apoptosis (programmed cell death) of rapidly dividing tumor cells.

After IV administration, Docetaxel Trihydrate is highly protein bound (greater than 95%) and extensively metabolized in the liver by the CYP3A4 enzyme system, with elimination mainly via the biliary/fecal route.

Daxotel is given only as a slow intravenous infusion over about 1 hour, through non-PVC tubing and containers (to avoid leaching), diluted in 250 mL of 0.9% sodium chloride or 5% dextrose solution to a final concentration of approximately 0.3-0.74 mg/mL. It must be administered in a hospital or specialized oncology infusion unit where vital signs can be monitored closely, especially during the first 10-15 minutes, and where facilities to manage severe hypersensitivity reactions (including anaphylaxis) are immediately available. Patients are not permitted to self-administer Daxotel at home.

Daxotel is metabolized mainly by the hepatic CYP3A4 enzyme, so drugs that alter CYP3A4 activity can significantly change docetaxel exposure and toxicity risk.

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, and other protease inhibitors): may substantially increase docetaxel plasma concentrations and toxicity; concurrent use should be avoided, and if unavoidable, close monitoring with dose reduction may be needed.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): may reduce docetaxel exposure and efficacy; avoid concurrent use where possible.
• Other myelosuppressive or hepatotoxic drugs: concurrent use may increase the risk of additive bone marrow suppression or liver toxicity; blood counts and liver function should be monitored closely.
• Live vaccines: should generally be avoided during and immediately after Daxotel therapy due to immunosuppression.

Always inform the treating oncologist of all prescription, over-the-counter, and herbal products being used before and during treatment.

Adverse effects of Daxotel are common and can be serious, requiring close medical monitoring throughout treatment.

Very Common

• Neutropenia, anemia, thrombocytopenia, febrile neutropenia and infections
• Hypersensitivity reactions (flushing, rash, itching, chest tightness, back pain, dyspnea, fever, chills)
• Peripheral neuropathy (numbness, tingling, pain), altered taste (dysgeusia)
• Fluid retention (edema, weight gain, pleural/pericardial effusion, ascites)
• Alopecia (hair loss), nail changes/disorders, skin reactions on hands and feet
• Nausea, vomiting, diarrhea, mucositis/stomatitis, constipation, anorexia
• Fatigue/asthenia, myalgia, arthralgia

Serious / Less Common

• Severe neutropenic sepsis and febrile neutropenia
• Severe hypersensitivity reactions including anaphylaxis
• Enterocolitis, neutropenic colitis, gastrointestinal perforation (rare, can be fatal)
• Severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
• Fluid overload leading to cardiac or pulmonary complications
• Cardiac arrhythmias, heart failure (rare)
• Secondary malignancies (leukemia) with long-term use

Patients should seek immediate medical attention for fever, signs of infection, severe shortness of breath, chest pain, severe rash, or signs of an allergic reaction during or after a Daxotel infusion.

Daxotel can cause fetal harm and is generally contraindicated during pregnancy based on its mechanism of action and animal reproduction data. Pregnancy status should be verified before starting treatment. Women of reproductive potential should use effective contraception during treatment with Daxotel and for at least 2 months after the final dose; male patients with female partners of reproductive potential should use effective contraception during treatment and for at least 4 months after the final dose. If pregnancy occurs during treatment, the patient should be advised of the potential risk to the fetus and referred for genetic counselling. Daxotel should be used in pregnancy only if the treating oncologist determines it is unavoidable and the potential benefit justifies the potential risk; consult a physician immediately in this situation.

Because of the potential for serious adverse effects in a breastfeeding infant, women should not breastfeed during treatment with Daxotel and for at least 1 week after the final dose; consult the treating physician regarding safe timing to resume breastfeeding.

Daxotel carries serious, potentially fatal risks and must only be given under the close supervision of a physician experienced in cancer chemotherapy, in a facility equipped to manage medical emergencies.

Boxed Warnings

• Hepatotoxicity/treatment-related mortality: Risk of toxic death is increased in patients with abnormal liver function, in those receiving higher doses, and in certain tumor types. Liver function should be assessed before each cycle; Daxotel should generally be avoided in patients with significant hepatic impairment.
• Severe hypersensitivity reactions: Including fatal anaphylaxis, can occur despite corticosteroid premedication, usually within minutes of starting the first or second infusion; the infusion facility must be equipped to manage such reactions.
• Severe fluid retention: Can occur despite premedication, presenting as peripheral edema, pleural effusion, ascites, or generalized edema; requires close monitoring.
• Severe neutropenia: Occurs in nearly all patients and can result in serious, life-threatening infection; complete blood counts should be checked frequently during treatment.

Additional Warnings

• Peripheral neuropathy may develop and can be severe; the treating physician may reduce the dose or discontinue treatment if this occurs.
• Enterocolitis and neutropenic colitis, which can be fatal, have been reported.
• Severe cutaneous adverse reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis) have rarely been reported.
• Risk of secondary malignancies (e.g., leukemia) with long-term follow-up.
• Effective contraception is required during and after treatment due to embryo-fetal risk (see Pregnancy and Lactation).
• Regular monitoring of complete blood counts and liver function tests is required throughout treatment with Daxotel.

There is no known specific antidote for Daxotel overdose. Expected complications of overdose include worsening of known adverse effects, particularly severe bone marrow suppression, peripheral neuropathy, and mucositis. Because Daxotel is administered only in a hospital or oncology setting under direct medical supervision, any suspected overdose should be managed immediately by the treating medical team with intensive supportive care, including hospitalization in a specialized unit, prophylactic granulocyte colony-stimulating factor if indicated, and management of specific symptoms as they arise. Anyone concerned about a possible overdose should seek immediate medical attention or contact emergency services.

Store unopened vials of Daxotel at 20°C-25°C (68°F-77°F) in the original carton to protect from bright light; brief excursions between 15°C-30°C are generally permitted. Do not freeze. Once a multi-dose vial is opened, it should be stored per the product label (commonly refrigerated at 2°C-8°C for a limited number of days) and discarded after the labelled in-use period. Diluted infusion solutions have a limited stability window and should be used promptly per pharmacy protocol. Daxotel should be stored, prepared, and disposed of by trained healthcare personnel only, following institutional hazardous-drug handling procedures, and kept out of reach of children and unauthorized personnel.

Pediatric use: The safety and efficacy of Daxotel in pediatric patients have not been established; it is not routinely used in children outside of clinical trials.

Geriatric use: No specific dose adjustment is generally required based on age alone, but elderly patients receiving Daxotel in combination regimens may have a higher incidence of certain severe adverse effects (e.g., febrile neutropenia) and should be monitored closely.

Hepatic impairment: Patients with elevated liver enzymes and bilirubin are at increased risk of severe toxicity; Daxotel should generally be avoided or dose-reduced in patients with significant hepatic impairment, per the treating physician's judgment (see Precautions and Warnings).

Renal impairment: No specific dose adjustment is established as necessary based on renal function; use with caution as data are limited.

Reproductive potential: See Pregnancy and Lactation for required contraceptive precautions.

The duration of treatment with Daxotel and the number of cycles administered are determined individually by the treating oncologist based on the specific cancer, treatment protocol (e.g., a fixed number of adjuvant cycles, or continued treatment until disease progression or unacceptable toxicity in the metastatic setting), and the patient's response and tolerability. Treatment is typically given in cycles of 3 weeks, with cycle number ranging from as few as 3-4 cycles (e.g., some head and neck regimens) to 6 cycles (adjuvant breast cancer) or continued longer-term in metastatic disease, always under close medical supervision.

Daxotel is generally supplied as a ready-to-use concentrate for solution for infusion, so no reconstitution step is needed for most currently marketed presentations; however, some older two-vial diluent-based formulations require initial mixing with the supplied diluent before further dilution - always check the specific product's package insert. In all cases, the required dose is subsequently withdrawn using a calibrated syringe and further diluted in a 250 mL infusion bag of 0.9% sodium chloride or 5% dextrose solution (non-PVC container) to achieve a final concentration of approximately 0.3-0.74 mg/mL, then gently inverted (not shaken) to mix. This preparation must be performed by trained pharmacy or oncology nursing personnel under aseptic, hazardous-drug handling conditions, and the diluted solution should be used within the timeframe specified by the manufacturer (commonly within 4-6 hours, including infusion time).

Antineoplastic agent; Taxane; Antimicrotubule agent (mitotic inhibitor)

Docetaxel Trihydrate promotes the assembly of tubulin into stable microtubules and inhibits their depolymerization, disrupting the microtubule network required for mitotic and interphase cellular functions. This stabilization arrests the cell cycle at the G2/M phase, preventing cell division, and triggers apoptosis in rapidly proliferating tumor cells.

D

The safety and efficacy of Daxotel have not been established in pediatric patients. It is not approved or routinely recommended for use in children, and pediatric use is generally limited to specialized clinical trial settings under pediatric oncology supervision.